Compare REED & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REED | ADVB |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.6M |
| IPO Year | 2009 | 2023 |
| Metric | REED | ADVB |
|---|---|---|
| Price | $0.82 | $8.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.7K | ★ 176.0K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 5.21 |
| Revenue | ★ $34,065,000.00 | N/A |
| Revenue This Year | $18.74 | N/A |
| Revenue Next Year | $18.00 | N/A |
| P/E Ratio | ★ N/A | $1.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.19 |
| 52 Week High | $5.97 | $24.23 |
| Indicator | REED | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 52.80 | 49.20 |
| Support Level | $0.76 | $3.95 |
| Resistance Level | $1.42 | $9.50 |
| Average True Range (ATR) | 0.11 | 1.02 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 69.59 | 56.49 |
Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.